RETEVMO

loxo oncology inc🇨🇦 Health Canada

Approval Id: 1eb69da6b23e3f47
Drug Approval Canada Name: RETEVMO
Product Name: RETEVMO
Status: Marketed
Status Date: 2022-01-21
Original Market Date: 2022-01-21
Din: 02516926
Drug Class: Human
Dosage Form: Capsule
Route Of Administration: Oral
Schedule: Prescription
Ahfs: 10:00.00
Atc Original: L01EX22 SELPERCATINIB
Atc Name: l 01 ex 22
Aig Number: 0162988002
Company Name: loxo oncology inc
Company Address: FL 9, 281 Tresser Blvd, Stamford, Connecticut, United States, 06901

SELPERCATINIB

80 MG

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

1eb69da6b23e3f47

Type

Standard